GARNL3

Across TCGA pan-cancer cohorts, GARNL3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated GARNL3 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GARNL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GARNL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SKCM, and UCEC are the cancer types where GARNL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.169	0.687	<.001	34	view →
SKCM	OS	Median	III,IV	0.179	0.814	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.875	0.302	.017	10	view →
THYM	DFS	Median	All	0.092	0.872	<.001	6	view →
UCS	OS	Median	All	0.153	0.687	.019	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
PRAD	DFS	Median	All	0.179	0.778	<.001	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GARNL3–LUAD (DFS)

Open the LUAD breakdown →